<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> is a third-generation <z:chebi fb="240" ids="33364,33400">platinum</z:chebi> compound with proven antitumor activity in the treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The occurrence of life-threating hemolitic uremic syndrome has been observed after <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> therapy </plain></SENT>
<SENT sid="2" pm="."><plain>The kind of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and treatment modalities seem to influence the <z:hpo ids='HP_0003674'>onset</z:hpo> of hemolitic uremic syndrome </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The clinical course of the case is reviewed and compared with reports of other similar cases in the literature </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: We describe the development of hemolitic uremic syndrome as a result of prolonged <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> treatment of a <z:hpo ids='HP_0003003'>colon cancer</z:hpo> patient </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: Although this rare event requires the concurrence of other unknown factors, it should be considered in a decision-making setting </plain></SENT>
</text></document>